O-{2-[(1,2,3-triazolyl)-4-[4-(N-maleimidomethyl)cyclohexane-1-carboxamidomethyl]]ethyl}-O'-[(N-diglycolyl-2-aminoethyl)-Gly-20-O-SN-38]heptaethyleneglycol | 1036969-18-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: O-{2-[(1,2,3-triazolyl)-4-[4-(N-maleimidomethyl)cyclohexane-1-carboxamidomethyl]]ethyl}-O'-[(N-diglycolyl-2-aminoethyl)-Gly-20-O-SN-38]heptaethyleneglycol
• 英文别名: CL1-SN-38；[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]methyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]acetate
• CAS: 1036969-18-2
• 化学式: C₆₁H₈₁N₉O₂₀
• 分子量: 1260.36
• InChiKey: NYXRQFYGTMLJGG-CELOCUEMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  90
• 可旋转键数：
  42
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  345
• 氢给体数：
  4
• 氢受体数：
  23

反应信息

• 作为产物：
  描述：

  O-(2-azidoethyl)-O'-[(N-diglycolyl-2-aminoethyl)-Gly-20-O-SN-38]heptaethyleneglycol 、 4-((2,5-二氧代-2,5-二氢-1H-吡咯-1-基)甲基)-N-(丙-2-炔-1-基)环己烷甲 在 copper(II) sulfate 、 sodium ascorbate 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 1.0h， 以65%的产率得到O-{2-[(1,2,3-triazolyl)-4-[4-(N-maleimidomethyl)cyclohexane-1-carboxamidomethyl]]ethyl}-O'-[(N-diglycolyl-2-aminoethyl)-Gly-20-O-SN-38]heptaethyleneglycol
  参考文献：
  名称：

  Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy

  摘要：

  CPT-11 is a clinically used cancer drug, and it is a prodrug of the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxycamptothecin). To bypass the need for the in vivo conversion of CPT-11 and increase the therapeutic index, bifunctional derivatives of SN-38 were prepared for use in anti body-based targeted therapy of cancer. The general synthetic scheme incorporated an acetylene-azide click cycloaddition step in the design, a short polyethylene glycol spacer for aqueous solubility, and a maleimide group conjugation. Conjugates of a humanized anti-CEACAM5 monoclonal antibody, hMN-14, prepared using, these SN-38 derivatives were evaluated in vitro for stability in buffer and human serum and for antigen-binding and cytotoxicity in a human colon adenocarcinoma cell line. Conjugates of hMN-14 and SN-38 derivatives 16 and 17 were found promising for further development.

  DOI：

  10.1021/jm800719t

文献信息

• Camptothecin-Binding Moiety Conjugates
  申请人：Govindan Serengulam V.

  公开号：US20100015046A1

  公开（公告）日：2010-01-21

  The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
• US8268317B2
  申请人：——

  公开号：US8268317B2

  公开（公告）日：2012-09-18
• US8834886B2
  申请人：——

  公开号：US8834886B2

  公开（公告）日：2014-09-16